Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “January 14, 2025”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 39    

Filtered results: 39

Finerenone for heart failure and risk estimated by the PREDICT-HFpEF model: A secondary analysis of FINEARTS-HF

McDowell K, et al. JAMA Cardiol. 2025;doi:10.1001/jamacardio.2025.0025

McDowell K, 01 03 2025

Efficacy and safety of finerenone in type 2 diabetes: A pooled analysis of trials of heart failure and chronic kidney disease

Ostrominki JW, et al. Diabetes Care. 2025;doi:10.2337/dc24-1873

Ostrominski JW, 01 02 2025

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial

Butt JH, et al. Lancet Diabetes Endocrinol. 2025;doi:10.1016/S2213-8587(24)00309-7

Butt JH, 01 02 2025

Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: A secondary analysis of the FINEARTS-HF randomized clinical trial

Cunningham JW, et al. JAMA Cardiol. 2025;doi:10.1001/jamacardio.2025.0016

Cunningham JW, 01 02 2025

A comprehensive exploration of FINEARTS-HF: A JACC theme issue

Krumholz HM, et al. JACC. 2025;doi:10.1016/j.jacc.2024.12.004

Krumholz HM, 01 01 2025

Did finerenone improve health status in the FINEARTS trial?: A critical reevaluation of the analysis of patient-reported outcomes in heart failure

Butler J, et al. JACC. 2025;doi:10.1016/j.jacc.2024.12.005

Butler J, 01 01 2025

Initial decline in glomerular filtration rate with finerenone in HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF

Matsumoto S, et al. JACC. 2025; doi:10.1016/j.jacc.2024.11.020

Matsumoto S, 01 01 2025

Clinical implications of mineralocorticoid receptor overactivation

Nigwekar SU, et al. Clinical Kidney Journal. 2025;doi:10.1093/ckj/sfae346

Nigwekar SU, 01 11 2024

Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: A secondary analysis of the FINEARTS-HF randomized clinical trial

Chimura M, et al. JAMA Cardiol. 2024;doi:10.1001/jamacardio.2024.4613.

Chimura M, 01 11 2024

Finerenone, obesity, and heart failure with mildly reduced/preserved ejection fraction: Prespecified analysis of FINEARTS-HF

Butt JH et al. JACC. doi: 10.1016/j.jacc.2024.10.111

Butt JH, 01 11 2024